Castle Biosciences, Inc. (CSTL)
NASDAQ: CSTL · Real-Time Price · USD
38.65
-0.97 (-2.45%)
At close: Dec 5, 2025, 4:00 PM EST
38.64
-0.01 (-0.03%)
After-hours: Dec 5, 2025, 5:01 PM EST
Castle Biosciences Income Statement
Financials in millions USD. Fiscal year is January - December.
Millions USD. Fiscal year is Jan - Dec.
Fiscal Year | TTM | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | 2019 - 2017 |
|---|---|---|---|---|---|---|---|
Period Ending | Sep '25 Sep 30, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 | Dec '20 Dec 31, 2020 | 2019 - 2017 |
| Revenue | 343.53 | 332.07 | 219.79 | 137.04 | 94.09 | 62.65 | Upgrade
|
| Revenue Growth (YoY) | 10.15% | 51.09% | 60.38% | 45.65% | 50.18% | 20.79% | Upgrade
|
| Cost of Revenue | 68.9 | 60.21 | 44.98 | 32.01 | 15.82 | 9.69 | Upgrade
|
| Gross Profit | 274.63 | 271.86 | 174.81 | 105.03 | 78.26 | 52.96 | Upgrade
|
| Selling, General & Admin | 222.56 | 200.05 | 180.15 | 143 | 86.74 | 48.13 | Upgrade
|
| Research & Development | 50.11 | 52.04 | 53.62 | 44.9 | 29.65 | 13.26 | Upgrade
|
| Amortization of Goodwill & Intangibles | 16.8 | 11.11 | 9.01 | 8.27 | 1.96 | - | Upgrade
|
| Operating Expenses | 289.47 | 263.19 | 242.78 | 196.17 | 118.34 | 61.39 | Upgrade
|
| Operating Income | -14.83 | 8.67 | -67.98 | -91.14 | -40.08 | -8.42 | Upgrade
|
| Interest Expense | -0.15 | -0.58 | -0.01 | -0.02 | -0 | -2.63 | Upgrade
|
| Interest & Investment Income | 12.25 | 12.92 | 10.62 | 3.97 | 0.07 | 0.37 | Upgrade
|
| Other Non Operating Income (Expenses) | 0.05 | - | - | - | - | - | Upgrade
|
| EBT Excluding Unusual Items | -2.69 | 21.01 | -57.37 | -87.19 | -40.01 | -10.69 | Upgrade
|
| Gain (Loss) on Sale of Investments | 3.88 | 0.56 | - | - | - | - | Upgrade
|
| Other Unusual Items | - | - | - | 18.29 | - | 0.49 | Upgrade
|
| Pretax Income | -18.92 | 21.56 | -57.37 | -68.9 | -40.01 | -10.2 | Upgrade
|
| Income Tax Expense | -6.68 | 3.32 | 0.1 | -1.77 | -8.72 | 0.08 | Upgrade
|
| Net Income | -12.24 | 18.25 | -57.47 | -67.14 | -31.29 | -10.28 | Upgrade
|
| Net Income to Common | -12.24 | 18.25 | -57.47 | -67.14 | -31.29 | -10.28 | Upgrade
|
| Shares Outstanding (Basic) | 29 | 28 | 27 | 26 | 25 | 19 | Upgrade
|
| Shares Outstanding (Diluted) | 29 | 29 | 27 | 26 | 25 | 19 | Upgrade
|
| Shares Change (YoY) | 1.04% | 9.15% | 2.87% | 3.65% | 32.80% | 118.63% | Upgrade
|
| EPS (Basic) | -0.43 | 0.66 | -2.14 | -2.58 | -1.24 | -0.54 | Upgrade
|
| EPS (Diluted) | -0.43 | 0.62 | -2.14 | -2.58 | -1.24 | -0.54 | Upgrade
|
| Free Cash Flow | 25.38 | 36.54 | -19.25 | -47.29 | -22.47 | 5.11 | Upgrade
|
| Free Cash Flow Per Share | 0.89 | 1.25 | -0.72 | -1.81 | -0.89 | 0.27 | Upgrade
|
| Gross Margin | 79.94% | 81.87% | 79.53% | 76.64% | 83.18% | 84.54% | Upgrade
|
| Operating Margin | -4.32% | 2.61% | -30.93% | -66.51% | -42.60% | -13.45% | Upgrade
|
| Profit Margin | -3.56% | 5.49% | -26.15% | -48.99% | -33.26% | -16.41% | Upgrade
|
| Free Cash Flow Margin | 7.39% | 11.00% | -8.76% | -34.51% | -23.88% | 8.16% | Upgrade
|
| EBITDA | 7.83 | 24.67 | -55.65 | -80.6 | -36.67 | -7.95 | Upgrade
|
| EBITDA Margin | 2.28% | 7.43% | -25.32% | -58.81% | -38.98% | -12.69% | Upgrade
|
| D&A For EBITDA | 22.66 | 16 | 12.33 | 10.54 | 3.41 | 0.47 | Upgrade
|
| EBIT | -14.83 | 8.67 | -67.98 | -91.14 | -40.08 | -8.42 | Upgrade
|
| EBIT Margin | -4.32% | 2.61% | -30.93% | -66.51% | -42.60% | -13.45% | Upgrade
|
| Effective Tax Rate | - | 15.39% | - | - | - | - | Upgrade
|
Source: S&P Capital IQ. Standard template. Financial Sources.